Intranasal drug delivery of small interfering RNA targeting Beclin1 encapsulated with polyethylenimine (PEI) in mouse brain to achieve HIV attenuation

Abstract

We previously reported that activation of the host autophagic protein, Beclin1, by HIV-1 infection represents an essential mechanism in controlling HIV replication and viral-induced inflammatory responses in microglial cells. Existing antiretroviral therapeutic approaches have been limited in their ability to cross the blood-brain barrier effectively and recognize and selectively eliminate persistent HIV-infected brain reservoirs. In the present study and for the first time, the bio-distribution and efficacy of noninvasive intranasal delivery of small interfering RNA (siRNA) against the Beclin1 gene using the cationic linear polyethylenimines (PEI) as a gene carrier was investigated in adult mouse brain. Fluorescein isothiocyanate (FITC)-labeled control siRNA delivered intranasally was found in the cytoplasm of neurons and glial cells of the prefrontal cortex at 4 and 24 hours post-delivery, with no major adverse immune reaction encountered. Intranasal delivery of the siRNA targeting Beclin1 significantly depleted the target protein expression levels in brain tissues with no evidence of toxicity. Binding of siRNA to PEI-polymer was characterized and confirmed by Raman spectroscopy. These results indicate that the intranasal drug delivery allows for the direct delivery of the PEI-siRNA nano-complex to the central nervous system, which could potentially offer an efficient means of gene silencing-mediated therapy in the HIV-infected brain.

Activation of cyclin D1 affects mitochondrial mass following traumatic brain injury

“…CyclinD1-RNAi (Santa Cruz Biotechnology) were administered to 8–12 weeks C57BL/6J mice through intranasal route using in vivo jetPEI (PolyPlus) transfection reagent as described previously with modifications (Bitko and Barik, 2008; Rodriguez et al, 2017). The RNAi-JetPEI complex was prepared according to the manufacturer’s protocol with modifications (Aigner, 2006; Rodriguez et al, 2017).…”

“…The RNAi-JetPEI complex was prepared according to the manufacturer’s protocol with modifications (Aigner, 2006; Rodriguez et al, 2017). Briefly, either the cyclinD1 RNAi or control RNAi along with JetPEI were separately diluted into half the injection volume in a 10% sterile glucose solution where the final glucose concentration would have to be 5%.…”

Sepsis: developing new alternatives to reduce neuroinflammation and attenuate brain injury

“…As of 2017, there were numerous studies published on animal models of Alzheimer's and Parkinson's diseases, and multiple sclerosis, among other diseases. The most frequently reported compounds administered by this route are growth factors, hormones, and molecules interfering or modifying the immune response, but as research in the area grows, interference RNAs may become another relevant group of intranasally administered compounds . The use of nanoparticles also expands the possibilities of the intranasal route.…”

Biomedical Nanotechnology Related Grand Challenges and Perspectives

“…Experts have suggested the development of least-component based nano-pharmacology wherein selected drug nano-carriers should be biocompatible and stimuli-responsive. Such materials can perform controlled drug delivery and release, even in the brain (Figure 1; Kaushik et al, 2016bKaushik et al, , 2019Nair et al, 2016;Rodriguez et al, 2017;Vashist et al, 2018a). f) Nanotechnology assisted combinational therapy is emerging as one of the best alternatives in conventional approaches.…”